These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19244026)

  • 1. Radiation therapy for neovascular age-related macular degeneration revisited.
    Kim IK; Gragoudas ES
    Br J Ophthalmol; 2009 Mar; 93(3):279-80. PubMed ID: 19244026
    [No Abstract]   [Full Text] [Related]  

  • 2. [New drug treatment for age-related macular degeneration].
    Stefánsson E; la Cour M; Helgadóttir G; Sigurdsson H; Jónasson F
    Laeknabladid; 2007 Apr; 93(4):299-301. PubMed ID: 17460341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy?
    Bopp S
    Br J Ophthalmol; 2007 Oct; 91(10):1259-60. PubMed ID: 17895411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.
    El-Mollayess GM; Noureddine BN; Bashshur ZF
    Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tachyphylaxis and bevacizumab.
    Avgikos KN; Horgan SE; Sivaraj RR; Hu K
    Ophthalmology; 2009 Sep; 116(9):1831-2; author reply 1832. PubMed ID: 19729101
    [No Abstract]   [Full Text] [Related]  

  • 6. Tachyphylaxis and bevacizumab.
    Ziemssen F; Neuhann IM; Voelker M
    Ophthalmology; 2009 Aug; 116(8):1591-2; author reply 1592-3. PubMed ID: 19651319
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ziemssen F; Heiduschka P; Schraermeyer U;
    Retina; 2007 Oct; 27(8):1154-6; author reply 1156-8. PubMed ID: 18040264
    [No Abstract]   [Full Text] [Related]  

  • 8. Ranibizumab for neovascular age-related macular degeneration.
    Gillies MC; Wong TY
    N Engl J Med; 2007 Feb; 356(7):748-9; author reply 749-50. PubMed ID: 17310523
    [No Abstract]   [Full Text] [Related]  

  • 9. Bevacizumab tachyphylaxis.
    Falavarjani KG; Modarres M
    Ophthalmology; 2009 May; 116(5):1016-7; author reply 1017. PubMed ID: 19410964
    [No Abstract]   [Full Text] [Related]  

  • 10. Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration.
    Klein RM; Klein RB
    Retina; 2007; 27(9):1163-5. PubMed ID: 18046218
    [No Abstract]   [Full Text] [Related]  

  • 11. Avastin and new treatments for AMD: where are we?
    Freeman WR; Falkenstein I
    Retina; 2006 Oct; 26(8):853-8. PubMed ID: 17031283
    [No Abstract]   [Full Text] [Related]  

  • 12. Radiation therapy for neovascular age-related macular degeneration.
    Kishan AU; Modjtahedi BS; Morse LS; Lee P
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):583-97. PubMed ID: 22975610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatments for macular degeneration: summarising evidence using network meta-analysis.
    Fadda V; Maratea D; Trippoli S; Messori A
    Br J Ophthalmol; 2011 Oct; 95(10):1476-7. PubMed ID: 21680571
    [No Abstract]   [Full Text] [Related]  

  • 14. Bevacizumab: a new hope?
    Madhusudhana KC; Newsom RS
    Eye (Lond); 2009 Sep; 23(9):1755-7. PubMed ID: 19741717
    [No Abstract]   [Full Text] [Related]  

  • 15. Ranibizumab therapy for neovascular age-related macular degeneration.
    Folk JC; Stone EM
    N Engl J Med; 2010 Oct; 363(17):1648-55. PubMed ID: 20961248
    [No Abstract]   [Full Text] [Related]  

  • 16. Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration.
    Hwang JC; Del Priore LV; Freund KB; Chang S; Iranmanesh R
    Ophthalmic Surg Lasers Imaging; 2011; 42(1):6-11. PubMed ID: 20954648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness.
    Brown G
    Curr Opin Ophthalmol; 2008 May; 19(3):175-6. PubMed ID: 18408489
    [No Abstract]   [Full Text] [Related]  

  • 18. Microperimetric changes after intravitreal bevacizumab for exudative age-related macular degeneration.
    Rensch F; Jonas JB
    Acta Ophthalmol; 2008 Sep; 86(6):696-7. PubMed ID: 18752522
    [No Abstract]   [Full Text] [Related]  

  • 19. Third nerve palsy following intravitreal anti-VEGF therapy for bilateral neovascular age-related macular degeneration.
    Micieli JA; Santiago P; Brent MH
    Acta Ophthalmol; 2011 Feb; 89(1):e99-100. PubMed ID: 19925526
    [No Abstract]   [Full Text] [Related]  

  • 20. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study.
    Sadda SR; Stoller G; Boyer DS; Blodi BA; Shapiro H; Ianchulev T
    Retina; 2010 Oct; 30(9):1390-9. PubMed ID: 20924261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.